Journals / DAHUDER Medical Journal / 2022 / Cilt: 2 - Sayı: 1

Etanercept-Induced Thrombocytopenia In A Patient With Ankylosing Spondylitis

Pages
28–29
Publication Date
2022-01-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report the case of a 40-year-old man diagnosed with Ankylosing spondylitis who developed Etanercept-induced isolated thrombocytopenia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tumor necrosis factor-alpha (TNF-α), which is produced by macrophages and activated T lymphocyte cells, plays a main role in inducing further stimulation of other inflammatory cells.
📊
Key Findings & Data:Anti-TNF-α drugs are used for induction and preservation of remission in patients with Ankylosing spondylitis.
💡
Conclusion & Impact:We report the case of a 40-year-old man diagnosed with Ankylosing spondylitis who developed Etanercept-induced isolated thrombocytopenia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Thrombocytopenia · Ankylosing Spondylitis · adverse effect

Abstract

Tumor necrosis factor-alpha (TNF-α), which is produced by macrophages and activated T lymphocyte cells, plays a main role in inducing further stimulation of other inflammatory cells. Anti-TNF-α drugs are used for induction and preservation of remission in patients with Ankylosing spondylitis. Etanercept, which is one of the most used Anti-TNF-α drugs, has side effects such as cytopenia but isolated thrombocytopenia is an uncommon adverse event. We report the case of a 40-year-old man diagnosed with Ankylosing spondylitis who developed Etanercept-induced isolated thrombocytopenia.

🔖

Cite This Article

ÖNMEZ, A., ALTUN, G., AKBAŞ, T., ÖNEÇ, B. (2022). Etanercept-Induced Thrombocytopenia In A Patient With Ankylosing Spondylitis. DAHUDER Medical Journal, Cilt: 2 - Sayı: 1, 28–29. https://ajindex.com/articles/850962

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Referans1. Khanna D, Mcmahon M, Furst DE. Safety Of Tumor Necrosis Factor alpha Antagonists Drug Saf 2004;27(5):307–24. Referans2. Keystone E. Safety Of Biologic Therapies—An Update. J Rheumatol 2005;32:8–12. Referans3. Cush JJ. Safety Of New Biologic Therapies İn Rheumatoid Arthritis. Bullet Rheum Dis 2003–04;52. Referans4. Malgarini RB, Pimpinella G. Etanercept And Methotrexate İn Rheumatoid Arthritis. Lancet 2004; 363(9422):1733. Referans5. Rheum Dis Clin North Am 2001;27:427–4 Referans6. Selby LA, Hess D, Shashidar H, De Villiers WJ, Selby LA. Crohn's Disease, İnfliximab And İdiopathic Thrombocytopenic Purpura.Inflamm Bowel Dis Sep 2004;10(5):698–700 Referans7. S. K. Pathare, C. Heycock, J. Hamılton Tnf Blocker-İnduced Thrombocytopenia Rheumatology 2006;45: 1313–1314. Referans8. M.J. Casanova A,⁎, M. Chaparro A, C, S. Martínez B, I. Vicuña B, J.P. Gisbert A, C Severe Adalimumab-İnduced Thrombocytopenia İn A Patient ith Crohn's Disease Journal Of Crohn's And Colitis (2012) 6, 1034–1037 Referans9. Valderílio Feijó Azevedo1, Marília Barreto Gameiro Silva2, Débora Karine Marinello3, Felipe Dunin Dos Santos4, Guilherme Barreto Gameiro Silva4 Leukopenia And Thrombocytopenia İnduced By Etanercept: Two Case Reports And Literature Review Rev Bras Reumatol 2011;52(1):107-112).